Suven Life Sciences Q3 FY19 results (Oct–Dec 2018) and concall

Suven Life Sciences reported a challenging Q3 FY19 with flat top-line and a 15% decline in bottom-line, attributed to postponed commercial CRAMS orders and raw material delays. Despite a downward revision for FY19, management projects a robust FY20 with significant top-line and bottom-line growth. A key strategic move is the demerger of the CRAMS business to unlock value and attract specialized investors, with the parent company retaining substantial cash for its discovery pipeline, including the anticipated SUVN-502 data readout in July.